Corrigendum to: Ciprofloxacin controlled-solid lipid nanoparticles: characterization, in vitro release, and antibacterial activity assessment (BioMed Research International (2017) 2017 (2120734) DOI: 10.1155/2017/2120734);Ciprofloxacin Controlled-Solid Lipid Nanoparticles: Characterization, in Vitro Release, and Antibacterial Activity Assessment

BioMed Research International

Volumn 2017, Issue , 2017, Pages

  Shazly, Gamal A ^a,b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b Assiut University   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; NANOCARRIER; SOLID LIPID NANOPARTICLE; ANTIINFECTIVE AGENT; DELAYED RELEASE FORMULATION; NANOPARTICLE; STEARIC ACID; STEARIC ACID DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DIFFUSION; DISPERSION; DISPERSITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; EMULSION; IN VITRO STUDY; INHIBITION ZONE; MELTING POINT; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; PHYSICAL CHEMISTRY; POLYMERIZATION; ROOM TEMPERATURE; SCANNING ELECTRON MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL; CHEMICAL MODEL; CHEMISTRY; DELAYED RELEASE FORMULATION; PHARMACOKINETICS;

ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; DELAYED-ACTION PREPARATIONS; MODELS, CHEMICAL; NANOPARTICLES; STEARIC ACIDS;

EID: 85011685349     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2017/6761452     Document Type: Erratum

References (39)

1. J. M. Blondeau, "Fluoroquinolones: mechanism of action, classification, and development of resistance, " Survey of Ophthalmology, vol. 49, no. 2, pp. S73-S78, 2004.
2. K. R.Wilhelmus, R. A. Hyndiuk, D. R. Caldwell, R. L. Abshire, A. T. Folkens, and L. B. Godio, "0.3% ciprofloxacin ophthalmic ointment in the treatment of bacterial keratitis.The Ciprofloxacin Ointment/Bacterial Keratitis Study Group, " Archives of Ophthalmology, vol. 11, pp. 1210-1218, 1993.
3. J. F. Acar and F.W. Goldstein, "Trends in bacterial resistance to fluoroquinolones, " Clinical Infectious Diseases, vol. 24, no. 1, pp. S67-S73, 1997.
4. L. M. Huneault, B. Lussier, P. Dubreuil, L. Chouinard, and C. Desévaux, "Prevention and treatment of experimental osteomyelitis in dogs with ciprofloxacin-loaded crosslinked high amylose starch implants, " Journal of Orthopaedic Research, vol. 22, no. 6, pp. 1351-1357, 2004.
5. W. Mehnert and K. Mäder, "Solid lipid nanoparticles: production, characterization and applications, " Advanced Drug Delivery Reviews, vol. 47, no. 2-3, pp. 165-196, 2001.
6. M. Radtke, E. B. Souto, and R. H. Müller, "Nanostructured lipid carriers: A novel generation of solid lipid drug carriers, " Pharmaceutical Technology Europe, vol. 17, no. 4, pp. 45-50, 2005.
7. C. W. Pouton, "Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system, " European Journal of Pharmaceutical Sciences, vol. 29, no. 3-4, pp. 278-287, 2006.
8. R. H. Müller, K.Mäder, and S. Gohla, "Solid lipid nanoparticles (SLN) for controlled drug delivery-A review of the state of the art, " European Journal of Pharmaceutics and Biopharmaceutics, vol. 50, no. 1, pp. 161-177, 2000.
9. S. Mukherjee, S. Ray, and R. S.Thakur, "Solid lipid nanoparticles: A modern formulation approach in drug delivery system, " IndianJournal of Pharmaceutical Sciences, vol. 71, no. 4, pp. 349-358, 2009.
10. R. H. Müller, S. Maaßen, H. Weyhers, and W. Mehnert, "Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407, " Journal of Drug Targeting, vol. 4, no. 3, pp. 161-170, 1996.
11. D.-B. Chen, T.-Z. Yang, W.-L. Lu, and Q. Zhang, "In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel, " Chemical and Pharmaceutical Bulletin, vol. 49, no. 11, pp. 1444-1447, 2001.
12. K. Manjunath, J. S. Ready, and V. Venkateswarlu, "Solid lipid nanoparticles as drug delivery systems, " Methods and Findings in Experimental and Clinical Pharmacology, vol. 27, no. 2, pp. 127-144, 2005.
13. I. P. Kaur, R. Bhandari, S. Bhandari, and V. Kakkar, "Potential of solid lipid nanoparticles in brain targeting, " Journal of Controlled Release, vol. 127, no. 2, pp. 97-109, 2008.
14. A. A. Attama, S. Reichl, and C. C. Müller-Goymann, "Diclofenac sodium delivery to the eye: in vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct, " International Journal of Pharmaceutics, vol. 355, no. 1-2, pp. 307-313, 2008.
15. S. C. Yang, L. F. Lu, Y. Cai, J. B. Zhu, B. W. Liang, and C. Z. Yang, "Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain, " Journal of Controlled Release, vol. 59, no. 3, pp. 299-307, 1999.
16. V. Jenning and S. H. Gohla, "Encapsulation of retinoids in solid lipid nanoparticles (SLN), " Journal of Microencapsulation, vol. 18, no. 2, pp. 149-158, 2001.
17. M. Schäfer-Korting, W. Mehnert, and H.-C. Korting, "Lipid nanoparticles for improved topical application of drugs for skin diseases, " Advanced Drug Delivery Reviews, vol. 59, no. 6, pp. 427-443, 2007.
18. N. Gandomia, E. Aboutaleba, M. Nooria et al., "Solid lipid nanoparticles of ciprofloxacin hydrochloride with enhanced antibacterial activity, " Journal of Nanoscience Letters, vol. 2, pp. 21-28, 2012.
19. M. Shah, Y. K. Agrawal, K. Garala, and A. Ramkishan, "Solid lipid nanoparticles of a water soluble drug, ciprofloxacin hydrochloride, " Indian Journal of Pharmaceutical Sciences, vol. 74, no. 5, pp. 434-442, 2012.
20. S.O.Tanjinatus, H. I. Ahsanul, D. Irin, andS.M. Ashraful Islam, "Comparative in vitro dissolution study of some ciprofloxacin generic tablets under biowaiver conditions by RP-HPLC, " International Journal of Pharmaceutical Science Research, vol. 2, pp. 3129-3135, 2011.
21. L. J. Waters, S. Bedford, and G. M. B. Parkes, "Controlled microwave processing applied to the pharmaceutical formulation of ibuprofen, " AAPS PharmSciTech, vol. 12, no. 4, pp. 1038-1043, 2011.
22. P. Pathak and M. Nagarsenker, "Formulation and evaluation of lidocaine lipid nanosystems for dermal delivery, " AAPS PharmSciTech, vol. 10, no. 3, pp. 985-992, 2009.
23. S. Kashanian, A. H. Azandaryani, and K.Derakhshandeh, "New surface-modified solid lipid nanoparticles using N-glutaryl phosphatidylethanolamine as the outer shell, " International journal of nanomedicine, vol. 6, pp. 2393-2401, 2011.
24. NanoComposix, NanoComposixs Guide to Dynamic Light Scattering Measurement and Analysis, Version 1.3, NanoComposix, San Diego, Calif, USA, 2012.
25. M. Gaumet, A. Vargas, R. Gurny, and F. Delie, "Nanoparticles for drug delivery: The need for precision in reporting particle size parameters, " European Journal of Pharmaceutics and Biopharmaceutics, vol. 69, no. 1, pp. 1-9, 2008.
26. A. Narala and K. Veerabrahma, "Preparation, characterization and evaluation of quetiapine fumarate solid lipid nanoparticles to improve the oral bioavailability, " Journal of Pharmaceutics, vol. 2013, Article ID 265741, 7 pages, 2013.
27. R. C. Doijad, F. V. Manvi, D. M. Godhwani, R. Joseph, and N. V. Deshmukh, "Formulation and targeting efficiency of cisplatin engineered solid lipid nanoparticles, " Indian Journal of Pharmaceutical Sciences, vol. 70, no. 2, pp. 203-207, 2008.
28. L. S. Kotikalapudi, L. Adepu, J. VijayaRatna et al., "Formulation and in vitro characterization of domperidone loaded solid lipid nanoparticles, " International Journal of Pharmacy and Biomedical Research, vol. 3, pp. 22-29, 2012.
29. M. El-Badry and M. Fathy, "Enhancement of the dissolution and permeation rates of meloxicam by formation of its freezedried solid dispersions in polyvinylpyrrolidone K-30, " Drug Development and Industrial Pharmacy, vol. 32, no. 2, pp. 141-150, 2006.
30. V. Sanna, G. Caria, andA.Mariani, "Effect of lipid nanoparticles containing fatty alcohols having different chain length on the ex vivo skin permeability of Econazole nitrate, " Powder Technology, vol. 201, no. 1, pp. 32-36, 2010.
31. H. Bunjes, K. Westesen, and M. H. J. Koch, "Crystallization tendency and polymorphic transitions in triglyceride nanoparticles, " International Journal of Pharmaceutics, vol. 129, no. 1-2, pp. 159-173, 1996.
32. A. Jain and S. K. Jain, "In vitro and cell uptake studies for targeting of ligand anchored nanoparticles for colon tumors, " European Journal of Pharmaceutical Sciences, vol. 35, no. 5, pp. 404-416, 2008.
33. J. Liu, T. Gong, C. Wang, Z. Zhong, and Z. Zhang, "Solid lipid nanoparticles loaded with insulin by sodium cholatephosphatidylcholine-based mixed micelles: preparation and characterization, " International Journal of Pharmaceutics, vol. 340, no. 1-2, pp. 153-162, 2007.
34. R. W. Korsmeyer, R. Gurny, E. Doelker, P. Buri, and N. A. Peppas, "Mechanisms of solute release from porous hydrophilic polymers, " International Journal of Pharmaceutics, vol. 15, no. 1, pp. 25-35, 1983.
35. R. W. Korsmeyer and N. A. Peppas, "Macromolecular and modeling aspects of swelling-controlled systems, " in Controlled ReleaseDelivery Systems, T. J. RosemanandS. Z.Mansdorf, Eds., pp. 77-90, Marcel Dekker, New York, NY, USA, 1983.
36. P. L. Ritger andN. A. Peppas, "A simple equation for description of solute release I. Fickian and non-fickian release from nonswellable devices in the form of slabs, spheres, cylinders or discs, " Journal of Controlled Release, vol. 5, no. 1, pp. 23-36, 1987.
37. J. Liu, T. Gong, C. Wang, Z. Zhong, and Z. Zhang, "Solid lipid nanoparticles loaded with insulin by sodium cholatephosphatidylcholine-based mixed micelles: Preparation and characterization, " International Journal of Pharmaceutics, vol. 340, no. 1-2, pp. 153-162, 2007.
38. K. Z. Vardakas, I. I. Siempos, A. Grammatikos, Z. Athanassa, I. P. Korbila, and M. E. Falagas, "Respiratory fluoroquinolones for the treatment of community-Acquired pneumonia: A metaanalysis of randomized controlled trials, " Canadian Medical Association Journal, vol. 179, no. 12, pp. 1269-1277, 2008.
39. P. M. W. Donaldson, A. P. Palleti, and M. P. Carroll, "Ciprofloxacin in general practice, " BMJ, vol. 308, no. 694, article 1437, 1994.